PDCD1 and cancer: Although immune checkpoint blockade (ICB), represented by anti-PD-1/L1, has changed cancer therapy, only a small percentage of cancer patients (10–30%) have a long-term clinical response (Topalian et al., 2012) (Khalil et al., 2016).